Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Benzinga.com  December 4, 2018

Aeterna Zentaris (AEZS) Receives Positive CHMP Opinion of Macimorelin for Diagnosis of Adult Growth Hormone Deficiency

GlobeNewswire November 19, 2018

55 Biggest Movers From Friday

Benzinga.com  November 19, 2018

Consolidated Research: 2018 Summary Expectations for Western Gas Partners, LP, HCA Healthcare, DHI Group, AEterna Zentaris, Tsakos Energy Navigation, and Acme United — Fundamental Analysis, Key Performance Indications

GlobeNewswire November 16, 2018

Aeterna Zentaris Reports Third Quarter 2018 Financial and Operating Results

GlobeNewswire November 6, 2018

Aeterna Zentaris Settles Dispute with Cogas Consulting, LLC

GlobeNewswire November 6, 2018

35 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  November 1, 2018

Aeterna Zentaris Announces Novo Nordisk to acquire rights to Macrilen™ in United States and Canada

GlobeNewswire November 1, 2018

Aeterna Zentaris to Announce Third Quarter 2018 Financial and Operating Results on November 6, 2018

GlobeNewswire October 31, 2018

Aeterna Zentaris Appoints Leslie Auld as Chief Financial Officer

GlobeNewswire September 25, 2018

Aeterna Zentaris Reports Second Quarter 2018 Financial and Operating Results

GlobeNewswire August 9, 2018

Aeterna Zentaris to Announce Second Quarter 2018 Financial and Operating Results on August 9, 2018

GlobeNewswire August 2, 2018

Aeterna Zentaris Appoints Olaf Althaus as General Manager and Managing Director of Aeterna Zentaris GmbH

GlobeNewswire May 31, 2018

Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting

GlobeNewswire May 8, 2018

28 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  May 8, 2018

Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Benzinga.com  May 8, 2018

Aeterna Zentaris Reports First Quarter 2018 Financial and Operating Results

GlobeNewswire May 7, 2018

Aeterna Zentaris to Announce First Quarter 2018 Financial and Operating Results on May 7, 2018

GlobeNewswire May 1, 2018

Aeterna Zentaris Files Management Information Circular

GlobeNewswire April 9, 2018

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2017 Financial and Operating Results

GlobeNewswire March 28, 2018